Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Mallinckrodt
Johnson and Johnson
Medtronic
Merck

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,052,987

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 8,052,987 protect, and when does it expire?

Patent 8,052,987 protects RECLAST and is included in one NDA.

This patent has forty-three patent family members in twenty-eight countries.

Summary for Patent: 8,052,987
Title:Method of administering bisphosphonates
Abstract: The invention relates to bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, and to methods of treatment using bisphosphonates. These bisphosphonates are used with satisfactory results for prolonged inhibition of bone resorption in conditions of abnormally increased bone turnover, e.g. osteoporosis, by intermittent administration, the periods between bisphosphonate administrations are longer than was previously considered appropriate, e.g. a dosing interval of at least about 6 months or less frequently.
Inventor(s): Horowitz; Zebulun D. (Basking Ridge, NJ), Richardson; Peter C. (Far Hills, NJ), Trechsel; Ulrich (Luzein, CH)
Assignee: Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:10/311,942
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,052,987
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,052,987

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis RECLAST zoledronic acid INJECTABLE;INTRAVENOUS 021817-001 Apr 16, 2007 AP RX Yes Yes   Start Trial   Start Trial TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,052,987

PCT Information
PCT FiledJune 18, 2001PCT Application Number:PCT/EP01/06850
PCT Publication Date:December 27, 2001PCT Publication Number: WO01/97788

International Family Members for US Patent 8,052,987

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 304856   Start Trial
Australia 2001274109   Start Trial
Australia 7410901   Start Trial
Brazil 0111806   Start Trial
Canada 2410201   Start Trial
China 1272013   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Moodys
Boehringer Ingelheim
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.